

ASX Announcement

Hong Kong & Singapore Racura Investor Briefings Update

9 April 2026

Racura Oncology Limited (“Racura”) is pleased to confirm the locations of its upcoming investor briefing events in Hong Kong and Singapore this month. The lunch briefings will provide investors with an opportunity to meet and talk with Racura management and learn about the company’s strategic and clinical development plans.

Hong Kong

Join Racura Oncology’s Executive Chair, Dr Pete Smith, for a lunch briefing and Q&A session.

Date: Tuesday, 14 April 2026

Time: 12.30pm-2.00pm (HKT)

Location: WeWork YF Life Tower - 13/F, YF Life Tower, 33 Lockhart Road, Wan Chai

Singapore

Join Racura Oncology’s CEO and Managing Director, Dr Daniel Tillett, together with Dimerix’s (ASX: DXB) Dr Nina Webster and Dr Rob Shepherd, for presentations and Q&A sessions with the two companies.

Date: Monday, 20 April 2026

Time: 12:30pm-2.30pm (SGT)

Location: The Fullerton Hotel (Inland Revenue Room) - 1 Fullerton Square, Singapore

RSVP Details

Interested parties are encouraged to RSVP by 9 April 2026 via: racura@irdepartment.com.au.

Please indicate which city briefing you are interested in attending and any dietary requirements.

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au